Seventy women with high-risk stage II (n = 10), IIIA Breast cancer remains an important source of morbidity and mortality among women, with an estimated 46 000 deaths annually in the United States alone.
Breast cancer remains an important source of morbidity and mortality among women, with an estimated 46 000 deaths annually in the United States alone. 1 Despite extensive (n = 12), IIIB (n = 11), or IV (n = 37) breast cancer research, recently published studies continue to report zero received cyclophosphamide 6000 mg/m 2 , etoposide or near-zero long-term progression-free survival rates 2400 mg/m 2 , and carboplatin 1200 mg/m 2 followed by among women with metastatic disease 2-7 and less than 50% infusion of autologous hematopoietic stem cells (AHSC).
long-term survival among women with locoregional disWomen with high-risk stage II disease had eight or ease. 8, 9 For example, a recently published 20-year followmore involved axillary lymph nodes (n = 9) or axillary up analysis 8 of a major adjuvant chemotherapy trial and breast relapse following lumpectomy, chemoreported 37% long-term progression-free survival among therapy, and radiation therapy (n = 1). Women with women with one to three involved axillary lymph nodes, measurable stage III or stage IV disease were required 26% progression-free survival among women with four to to demonstrate complete or partial response to conven-10 axillary nodes involved, and no long-term progressiontional-dose chemotherapy prior to transplant. The overfree survivors among women with more than 10 involved all (complete plus partial) response rate for the 31 nodes. Similarly, a recently reported large chemotherapy patients not in complete remission at the time of transtrial in women with previously untreated metastatic disease plant was 55%. With a median follow-up of 545 days, reported a 0% survival rate at less than 5 years.
7 the 2-year actuarial progression-free survival rates for Disappointing long-term results with conventional-dose patients with stage II, IIIA, IIIB and IV are 86, 75, 42 therapy, as well as both controlled and uncontrolled studies and 13%, respectively. Factors independently predictive suggesting a chemotherapeutic dose-response relationship of longer progression-free survival by multivariate for breast cancer within conventional dose ranges [7] [8] [9] have analysis included lower stage disease, status of disease led to the introduction of high-dose therapy (HDC) folat transplant (in CR vs not in CR), and positive estrogen lowed by rescue with autologous blood or marrow-derived receptor status. Factors predictive of more rapid neuhematopoietic stem cells (AHSC) in women with metastatic trophil engraftment by multivariate analysis included or high-risk non-metastatic breast cancer. Table 1 Patient characteristics time that the study was being designed, 10 and were not considered for use in the present trial.
n (%)

Age at transplant (years)
Patients and methods 20- both marrow and blood-derived stem cells whereas later in Combined marrow and blood 30 (42.9) the study (following the publication of additional studies Three stem cell mobilization studies were approved by the Temple University IRB and utilized as accessory protoa One patient (UPN 108) was rescued with bone marrow alone; this patient cols during the course of this study. Thus, blood-derived did not undergo mobilization. stem cells were obtained via multiple peripheral blood leukapheresis procedures following: (1) mobilization with G-CSF 10 g/kg/day s.c. administered for 4 days; or (2) G-12 h for six doses on day −6 to day −4 for a total dose of 2400 mg/m 2 , and carboplatin 300 mg/m 2 per day as 24-h CSF preceded by the administration of cyclophosphamide 3000 mg/m 2 i.v. × 1; or (3) GM-CSF as previously intravenous infusions beginning on day −6 to day −3 for a total dose of 1200 mg/m 2 . Dose adjustments based on ideal decribed 42 (Table 1) . One patient (UPN 108) underwent bone marrow harvesting alone and was thus not mobilized. body weight were made for overweight patients. DMSOcryopreserved stem cells were infused beginning on day 0. Leukaphereses, progenitor cell enumeration, and cryopreservation were performed as previously described. 42 Collections greater than approximately 10 cc/kg were split into two aliquots and infused on day 0 and day +1. The high-dose regimen consisted of cyclophosphamide 1500 mg/m 2 per day as a 1-h intravenous infusion daily for Decisions regarding pre-and/or post-transplant administration of radiation therapy were made on a patient-byfour days from day −6 to day −3 for a total dose of 6000 mg/m 2 , etoposide 400 mg/m 2 as 1-h infusion every patient basis by the individual attendings based primarily on the perceived risk of relapse in areas of known disease Statistical methods and the perceived ability of the bone marrow to tolerate All raw data were subjected to detailed computer-assisted radiation in the post-transplant period.
error detection prior to the initiation of the statistical analysis. Data were analyzed according to the most recent follow-up as of 15 July 1996. Overall and progression-free Supportive care survival rates and neutrophil engraftment rates were calculated according to the method of Kaplan and Meier. 44 UniPatients were treated in a dedicated inpatient bone marrow variate and multivariate associations involving the above transplant unit in single-bed hospital rooms equipped with variables were evaluated with the log rank test, and Cox laminar airflow (LAF) or high efficiency positive pressure proportional hazards regression, respectively. 44 air (HEPA) filtration. The prophylactic antibiotic regimen Patients tabulated as having been in 'complete remission in all patients consisted of ciprofloxacin 500 mg p.o. twice at any time prior to transplant' may or may not have been a day administered from hospital admission to neutrophil in remission at the actual time of the transplant -as detailed engraftment, acyclovir 800 mg p.o. twice a day adminisbelow, a separate variable to capture the latter data element tered from day −3 to day +100, and fluconazole 400 mg was included and analyzed separately with respect to its p.o. daily from hospital admission to neutrophil effect on survival. engraftment. Initial coverage for neutropenic fevers con-
All P values are two-sided. All data entry, data checking, sisted of ceftazidime 1 g i.v. q 8 h in conjunction with and data analyses were performed with SAS statistical vancomycin 1 g i.v. q 12 h, with amphotericin B 0.3-software (SAS Institute, Cary, NC, USA). 0.8 mg/kg/day added for refractory fevers or deteriorating clinical status. Patients received G-CSF 5 g/kg/day beginning at day +1 as a short i.v. infusion and continued to the Results date of stable neutrophil engraftment, except for 15 patients who received no HGF in the post-transplant period due to participation in a previously published randomized trial, 43 Patient characteristics and one patient (UPN 108) who received GM-CSF Seventy patients were transplanted on this protocol between 7 g/kg/day starting at day +1.
26 November 1991 and 31 October 1995. The median age was 42 years (range 26-63). As of the closing date (15 July 1996) , the median follow-up of surviving patients was 545 Evaluation of engraftment, response and toxicity days (range 278-1563 days). Patients had received a median of six cycles of conventional-dose chemotherapy The date of neutrophil engraftment was taken as the date prior to transplant (range 0-20). The median ECOG peron which the absolute peripheral blood neutrophil count formance status at transplant was 0 (range 0-1). Patients first recovered to a sustained count of 0.5 × 10 9 /l or greater. with stage II disease had a median of 11 positive lymph The date of platelet engraftment was taken as the first date nodes (range 8-23 except for one patient (UPN 134) who on which the patient achieved a sustained unsupported perihad only two positive axillary lymph nodes at diagnosis but pheral blood platelet count of 20 × 10 9 /l. The number of was judged to have high-risk disease following the developdays required to achieve neutrophil and platelet ment of progressive disease in the breast and axilla shortly engraftment were calculated based on the date on which following the completion of lumpectomy, axillary lymph the infusion of stem cells began.
node dissection, six cycles of conventional chemotherapy, Routine disease restaging was scheduled at 3, 6 and 12 and 4680 cGy irradiation to the chest wall and axilla). months following transplant, and annually thereafter, and Among patients with stage IV disease, 62% had bone corconsisted of a history and physical examination, a complete tex involvement, 22% had bone marrow involvement, 14% blood chemistry panel, a CT scan of the chest, abdomen had liver involvement, 32% had lung involvement, 24% and pelvis, and a bone scan. Additional interim restaging had mediastinal involvement, and 38% had involvement of took place as clinically indicated. Complete response was non-axillary lymph nodes. Other patient characteristics are defined as disappearance of all evidence of active disease.
shown in Table 1 . For the purposes of this study, disappearance of all measurable disease in conjunction with stable or resolving bone scans over a period of a minimum of 3 months from the Toxicity date of the transplant was also defined as a complete response. Partial reponse was defined as a 50% or greater As summarized in Table 2 , commonly observed toxicities included neutropenia, thrombocytopenia, anemia, mucosreduction in cross-sectional diameter of all measurable lesions.
itis, nausea, vomiting, diarrhea, and skin rash. All patients developed at least one episode of febrile neutropenia requirToxicities were graded according to standard Southwest Oncology Group (SWOG) toxicity grading criteria except ing non-prophylactic antibiotics. One patient (UPN 147), a 58-year-old woman with stage for oral or esophageal mucositis which were graded as follows: grade 1, mild erythema or discomfort; grade 2, mod-IIIA disease who was receiving low-dose steroids for mild pre-existing systemic lupus erythematosis at the time of the erate discomfort; grade 3, patient required parenteral narcotics for pain control; grade 4, grossly hemorrhagic transplant, died at day +53 following the development of hepatic veno-occlusive disease, gram-positive bacteremia, mucositis.
276 Table 2 Summary of observed toxicities a were attributable to progressive disease.
Four additional patients (UPN 273, UPN 300, UPN 339
Combined (n = 30) 11 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) and UPN 372) required transient ICU admission for,
Stage of disease II (n = 10) 11 (9) (10) (11) (12) respectively, bacteremia due to vancomycin-resistant IIIA (n = 12) 11 (9-21) 0.0474 d enterococcus, immediate-onset hypotensive and hypoxic IIIB (n = 11) 12 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) reaction to a platelet transfusion, apparent septic shock IV (n = 37) 12 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) responding junction with rapid multifocal progression of her underlying cancer. Three patients (in addition to UPN 147, decribed above) transiently satisfied the Seattle criteria 45 for poietic growth factors following transplant; (2) infusion of a higher number of CFU-GM/kg; (3) mobilization with Ghepatic veno-occlusive disease but all recovered spontaneously.
CSF or cyclophosphamide plus G-CSF (vs mobilization with GM-CSF or no mobilization); and (4) lower stage disease (Table 3) .
Engraftment and transfusion support
The median number of days required to attain an unsupported peripheral blood platelet count of 20 000/l or All 70 patients achieved sustained neutrophil engraftment. The median time to achieve 500 polys/l in the peripheral greater was 14 days (range 9-39 days); the rate of platelet engraftment was highly correlated with the rate of neutroblood was 11 days (range 9-24 days). Associations between selected factors and the rate of neutrophil engraftment are phil engraftment (P Ͻ 0.001). The median number of platelet transfusions administered was four (interquartile range shown in Table 3 . Multivariate Cox proportional hazards analysis revealed that the following factors were indepen-2-6). The median number of units of red cells transfused was dently predictive of a shorter interval between transplant and neutrophil engraftment: (1) administration of hematofour (interquartile range 4-6). The median interval between the transplant and the date of the last red cell transfusion Discussion was 10.5 days (range 2-41 days).
This study demonstrates that the combination of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) conResponse and survival stitutes an active and well-tolerated regimen in the treatment of women with high-risk non-metastatic or metastatic Fifty of the 70 patients (71%) achieved or remained in combreast cancer. As noted, only one of the 70 patients (1.4%) plete remission for a minimum of 3 months following the died of any cause prior to day 100, and the 2-year actuarial transplant, whereas two patients (3%) achieved a partial progression-free survival rates among patients with highremission, three patients (4%) were judged to have stable risk stage II, stage IIIA, stage IIIB and stage IV disease disease for a minimum of 3 months, and 14 patients (20%) were 86, 75, 42 and 13%, respectively. developed progressive disease within 3 months following
The incidence of treatment-related mortality (1.4%) the transplant. One patient (UPN 147, 1.4%) was not evaluobserved in the present study is lower than has able for reponse due to death prior to day 100. Of the 31 been reported in many recently reported studies patients who were not in complete remission at the time of high-dose therapy followed by autologous stem cell of transplant, 15 (48%) achieved a complete remission a or bone marrow rescue in women with breast canminimum of 3 months following transplant.
cer. 11, 12, 14, 15, 17, 19, 20, 22, 23, 26, 27, 29, 32, 33 For example, in a recently The actuarial median overall survival of the study popureported phase II study 27 of the popular 10, 17, [26] [27] [28] cyclophoslation as a whole was 719 days. As of the closing date phamide-cisplatin-carmustine (CCB) regimen, Peters et al 27 the actuarial median overall survival had not been reached reported 10 treatment-related deaths among 102 women among stage II or stage IIIA patients, and was 1165 days with high-risk breast cancer. Although comparisons among and 575 days for stage IIIB patients and stage IV phase II trials must be made with caution, the low treatpatients, respectively. ment-related mortality observed in the present trial, along The 2-year actuarial progression-free survival rates for with the observation that the stage-specific response and patients with stage II, stage IIIA, stage IIIB, and stage IV progression-free survival rates observed in the present trial disease are 86, 75, 42 and 13%, respectively. Associations are comparable to those reported in other recently reported between other factors and the probability of progressiontrials of HDC in women with metastatic or non-metastatic free survival are summarized in Table 4 . Factors indepenbreast cancer, and the favorable efficacy and tolerdently predictive of progression-free survival included: (1) ability observed in several other recently reported trials of stage of disease prior to transplant; (2) status of disease (in high-dose CEC in the treatment of a variety of malig-CR vs not in CR) at the time of the transplant; and (3) nancies, [46] [47] [48] [49] [50] [51] [52] suggest that a phase III trial comparing CCB estrogen receptor status (Table 4) .
with CEC may be warranted. Multivariate analysis of progression-free survival among
Two recently published smaller studies also suggest that patients with stage IV disease revealed that estrogen recephigh-dose CEC has a faborable risk-benefit ratio in women tor status, number of sites of metastatic disease, and disease with breast cancer. In 1993, Kritz et al 24 reported treating status at transplant were independently predictive of 18 patients with metastatic breast cancer with high-dose progression-free survival within this subset.
CEC. Of note, eight of the 18 patients (44%) remained alive Nine patients had developed chest wall involvement and progression-free 10-18 months post-transplant, a figure prior to the transplant but had not developed distant metawhich compares favorably with other recently reported stases and were considered to have non-metastatic disease trials of high-dose therapy for metastatic disease. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [28] [29] [30] [31] [32] [33] for the purposes of this study. The median progression-free More recently, Broun et al 15 reported treating 28 women survival among these nine patients was 2.09 years. In conwith metastatic breast cancer with tandem autotransplantrast, the 24 patients with non-metastatic disease without tation utilizing high-dose CEC. The progression-free surprior chest wall involvement had not reached their median vival rate was 32% with a median follow-up of 23 months, progression-free survival as of the closing date (P = 0.15).
and only one patient (3.6%) died from treatment-related causes. Few published trials of HDC followed by autologous Sites of progression HSC rescue in patients with metastatic or high-risk nonmetastatic breast cancer have included formal analyses of The correlation between sites of involvement prior to transplant and sites of progression following transplant was varifactors predictive of survival or engraftment rate. As noted, factors found to be independently predictive of progressionable depending upon the site. For example, 15 of the 26 patients with progression involving the bone cortex (58%) free survival in the present study included stage of disease, status of disease at transplant (in CR vs not in CR), and had recognized bone cortex involvement prior to transplant, whereas only three of the 13 patients with progression estrogen receptor status. Recently, Ayash et al, 12 in a study of 62 women with metastatic breast cancer undergoing involving the liver (23%) had recognized liver involvement prior to transplant. Seven of the 15 patients with pro-HDC followed by infusion of AHSC, reported that attainment of a CR with induction chemotherapy and involvegression involving the lung parenchyma (47%) had recognized lung parenchymal involvement prior to transplant. ment of a single (as opposed to multiple) metastatic site were independently predictive of prolonged progressionThere was no correlation between the administration of radiation therapy in the pre-or post-transplant period and free survival. In contrast to the study of Ayash et al, 12 Dunphy et al, 16 the incidence of relapse in bone. in a study of 80 women undergoing HDC followed by independent statistical significance for each of the above factors except for stage of disease which was not studied. infusion of AHSC for metastatic breast cancer, reported three entirely different factors as having independent progIn summary, the present study suggests that high-dose CEC followed by infusion of AHSC constitutes an active nostic significance with regard to overall survival, ie liver involvement by tumor, soft tissue involvement by tumor, and well-tolerated regimen in women with high-risk nonmetastatic or metastatic breast cancer; direct comparison and prior adjuvant chemotherapy. The present study appears to support the concept that the extent of pre-transagainst other commonly used regimens such as CCB may be warranted. plant chemotherapy is associated with a less favorable prognosis; as noted in Table 4 , a strong univariate trend (P = 0.007) towards extended survival among patients References exposed to fewer than six cycles of pre-transplant chemotherapy was observed. However, the possibility that more rates calculated in our analysis may underestimate the effi- 
